What is SAB Biotherapeutics Forward Dividend Yield %?
As of today (2024-06-06), the Forward Annual Dividend Yield of SAB Biotherapeutics is 0.00%.
As of today (2024-06-06), the Trailing Annual Dividend Yield of SAB Biotherapeutics is 0.00%.
SABS's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.685 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of SAB Biotherapeutics's Forward Dividend Yield %
For the Biotechnology subindustry, SAB Biotherapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SAB Biotherapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where SAB Biotherapeutics's Forward Dividend Yield % falls into.
SAB Biotherapeutics Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
SAB Biotherapeutics (NAS:SABS) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
SAB Biotherapeutics Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of SAB Biotherapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
SAB Biotherapeutics (SAB Biotherapeutics) Business Description
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SABS has been successfully added to your